PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Belite Bio Inc ADR (BLTE)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS07782B1044
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$994.68M
EPS-$1.19
EBITDA (TTM)-$31.53M
Year Range$11.00 - $48.60
Target Price$56.50
Short %0.33%
Short Ratio0.76

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Belite Bio Inc ADR

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Belite Bio Inc ADR, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


0.00%100.00%200.00%300.00%400.00%NovemberDecember2024FebruaryMarchApril
258.83%
22.18%
BLTE (Belite Bio Inc ADR)
Benchmark (^GSPC)

S&P 500

Returns By Period

Belite Bio Inc ADR had a return of -16.94% year-to-date (YTD) and 28.94% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-16.94%5.84%
1 month-12.60%-2.98%
6 months-0.78%22.02%
1 year28.94%24.47%
5 years (annualized)N/A11.44%
10 years (annualized)N/A10.46%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-5.07%6.49%-17.04%
2023-7.28%17.77%12.16%8.75%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BLTE is 64, suggesting that the investment has average results relative to the market in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.

The Risk-Adjusted Performance Rank of BLTE is 6464
Belite Bio Inc ADR(BLTE)
The Sharpe Ratio Rank of BLTE is 6262Sharpe Ratio Rank
The Sortino Ratio Rank of BLTE is 6464Sortino Ratio Rank
The Omega Ratio Rank of BLTE is 6666Omega Ratio Rank
The Calmar Ratio Rank of BLTE is 6767Calmar Ratio Rank
The Martin Ratio Rank of BLTE is 6262Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Belite Bio Inc ADR (BLTE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


BLTE
Sharpe ratio
The chart of Sharpe ratio for BLTE, currently valued at 0.35, compared to the broader market-2.00-1.000.001.002.003.004.000.35
Sortino ratio
The chart of Sortino ratio for BLTE, currently valued at 1.05, compared to the broader market-4.00-2.000.002.004.006.001.05
Omega ratio
The chart of Omega ratio for BLTE, currently valued at 1.15, compared to the broader market0.501.001.501.15
Calmar ratio
The chart of Calmar ratio for BLTE, currently valued at 0.36, compared to the broader market0.002.004.006.000.36
Martin ratio
The chart of Martin ratio for BLTE, currently valued at 1.18, compared to the broader market0.0010.0020.0030.001.18
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.05, compared to the broader market-2.00-1.000.001.002.003.004.002.05
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.98, compared to the broader market-4.00-2.000.002.004.006.002.98
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.36, compared to the broader market0.501.001.501.36
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.55, compared to the broader market0.002.004.006.001.55
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.05, compared to the broader market0.0010.0020.0030.008.05

Sharpe Ratio

The current Belite Bio Inc ADR Sharpe ratio is 0.35. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.


Rolling 12-month Sharpe Ratio0.000.501.001.502.002.503.00NovemberDecember2024FebruaryMarchApril
0.35
2.05
BLTE (Belite Bio Inc ADR)
Benchmark (^GSPC)

Dividends

Dividend History


Belite Bio Inc ADR doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-35.00%-30.00%-25.00%-20.00%-15.00%-10.00%-5.00%0.00%NovemberDecember2024FebruaryMarchApril
-20.85%
-3.92%
BLTE (Belite Bio Inc ADR)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Belite Bio Inc ADR. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Belite Bio Inc ADR was 74.59%, occurring on Jun 23, 2023. Recovery took 120 trading sessions.

The current Belite Bio Inc ADR drawdown is 20.85%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-74.59%Jul 6, 2022244Jun 23, 2023120Dec 13, 2023364
-32.66%Feb 15, 202443Apr 17, 2024
-23.75%May 9, 20228May 18, 202215Jun 9, 202223
-19.49%Jun 27, 20223Jun 29, 20222Jul 1, 20225
-16.24%May 2, 20221May 2, 20221May 3, 20222

Volatility

Volatility Chart

The current Belite Bio Inc ADR volatility is 21.68%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%NovemberDecember2024FebruaryMarchApril
21.68%
3.60%
BLTE (Belite Bio Inc ADR)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Belite Bio Inc ADR over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items